| Titre : | Adenoid cystic carcinoma of Bartholin's gland, a case report with genomic data and literature review (2023) |
| Auteurs : | C. Evin ; P.-A. Just ; B. Borghese ; E. Fabiano ; S. Bennani ; E. Canny ; L. Marisa ; N. Derive ; P. Laurent-Puig ; J. Alexandre ; C. Durdux |
| Type de document : | Article |
| Dans : | Cancer/Radiothérapie (Vol. 27, n°4, juin 2023) |
| Article en page(s) : | p. 328-336 |
| Note générale : | https://doi.org/10.1016/j.canrad.2023.01.001 |
| Langues: | Anglais |
| Descripteurs : |
HE Vinci Carcinome adénoïde kystique ; Radiothérapie ; Tumeurs de la vulve |
| Mots-clés: | Glande de Bartholin ; Glandes vestibulaires majeures ; Radiothérapie profil génomique |
| Résumé : | Adenoid cystic carcinoma of the Bartholin's gland (ACCBG) is a rare, slowly but aggressive malignancy. We reported the case of a 31-year-old woman who was treated by local excision and then hemi-vulvectomy, with positive margins and perineural invasion. Radiation therapy (RT) was then performed delivering 45Gy in 25 fractions in bilateral inguinal lymph nodes and 64.8Gy in 36 fractions on the vulvar area. After 30 months, there was no local relapse (LR) but the patient presented a histologically documented lung recurrence. Genomic profiling of the tumor showed a MYB-NFIB fusion transcript and a somatic mutation of PLCG1. A treatment by Lenvatinib was started. We conducted a literature review of 100 published cases. Patients were mainly treated by radical vulvectomy (30%), hemi-vulvectomy (17%), wide or local excision (21% and 24%, respectively) or other. Forty-four percent of patients received postoperative RT, more frequently in case of positive margin (71.9% versus 29.5%). RT may reduce the risk of LR regardless of margin status, with 15.4% vs. 41.9% of LR with or without RT, respectively, in patients with negative margins, and 13% vs. 33.3% of LR with or without RT, respectively, in patients with positive margins. The risk of relapse of any type was 40.9% in patients who received adjuvant RT vs. 48.2% in patients who did not. Median time to relapse was 24 months (range 6-156 months). The most frequent metastatic sites were lung (76.7%) and bone (26.7%). Optimal treatment for ACCBG is still not clearly defined but pooling the data from published case report help us better understand this rare disease and help in the therapeutic decision. |
| Disponible en ligne : | Oui |
| En ligne : | https://login.ezproxy.vinci.be/login?url=https://www.sciencedirect.com/science/article/pii/S1278321823000082 |
Bibliothèques HE Vinci
